MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12916-025-03985-4

Медицинская библиотека · BMC medicine · 2025

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

Jiang Yaofei, Bei Weixin, Wang Lin, Lu Nian, Xu Cheng, Liang Hu, Ke Liangru, Ye Yanfang, He Shuiqing, Dong Shuhui, Liu Qin, Zhang Chuanrun, Wang Xuguang, Xia Weixiong, Zhao Chong, Huang Ying, Xiang Yanqun, Liu Guoying

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.

METHODS

In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety.

RESULTS

Twenty-five patients were enrolled (84% male; median age 44 years (range, 24-60)), with a median follow-up of 10.2 months. The ORR was 68%, with 3 complete responses, 14 partial responses, and 6 stable diseases. The median DoR was 9.1 months (95% CI, 3.8-14.5 months). The median PFS was 10.6 months (95% CI, 5.2-16.0 months). The 12-month OS was 75.6%. Treatment was well tolerated. Grade 3 or 4 treatment-related adverse events occurred in 12 (48%) patients. Fourteen patients (56%) experienced potentially immune-related adverse events (irAEs). One patient experienced a grade 3 immune-related rash and another patient had grade 3 immune-related lipase increased. No treatment-related death occurred.

CONCLUSIONS

Cadonilimab in combination with TPC chemotherapy demonstrated promising antitumoral efficacy and manageable toxicities in patients with RM-NPC who failed frontline immunotherapy. Further trials are warranted to confirm and expand these findings.

TRIAL REGISTRATION: This trial was registered at chictr.org.cn (ChiCTR2200067057).

Для цитирования: Jiang Yaofei, Bei Weixin, Wang Lin, Lu Nian, Xu Cheng, Liang Hu, Ke Liangru, Ye Yanfang, He Shuiqing, Dong Shuhui, Liu Qin, Zhang Chuanrun, Wang Xuguang, Xia Weixiong, Zhao Chong, Huang Ying, Xiang Yanqun, Liu Guoying. Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.. BMC medicine. 2025. DOI: 10.1186/s12916-025-03985-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.